Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies

  • Andrei Iagaru
  • Camila Mosci
  • David W. Dick
  • Mike Sathekge
  • Paula Lapa
  • Joao M. de Lima
  • Sanjiv Sam Gambhir
Letter to the Editor

References

  1. 1.
    Critical considerations on the combined use of 18F-FDG and 18F-fluoride for PET assessment of metastatic bone disease (authors Gang Cheng & Thomas C. Kwee & Sandip Basu & Abass Alavi) Eur J Nucl Med Mol Imaging (2013) 40:1141–1145 doi: 10.1007/s00259-013-2459-y
  2. 2.
    Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med. 2013;54:176–83. doi: 10.2967/jnumed.112.108803.PubMedCrossRefGoogle Scholar
  3. 3.
    Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501–5. doi: 10.2967/jnumed.108.058339.PubMedCrossRefGoogle Scholar
  4. 4.
    Lin F, Rao J, Mittra E, Nallapareddy K, Chengapa A, Dick D, et al. Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging. 2012;39:262–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Bailey D. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future? J Nucl Med. 2010;51:165–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Basu S, Rao R. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future? J Nucl Med. 2010;51:165.PubMedCrossRefGoogle Scholar
  7. 7.
    Iagaru A, Mittra E, Goris ML, Gambhir SS. Reply: combined 18F-FDG and fluoride approach in PET/CT imaging: is there a clinical future? J Nucl Med. 2010;51:166–7. doi: 10.2967/jnumed.109.067082.CrossRefGoogle Scholar
  8. 8.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMedGoogle Scholar
  9. 9.
    Ben Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:408–15.PubMedCrossRefGoogle Scholar
  10. 10.
    Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Iagaru A, Mittra E, Dick D, Gambhir S. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Feldman F, van Heertum R, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol. 2003;32:201–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Jadvar H, Pinski J, Conti P. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003;10:1485–8.PubMedGoogle Scholar
  14. 14.
    Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara N, Sato H, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012;26:138–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Jadvar H, Desai B, Ji L, Conti P, Dorff T, Groshen S, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Krüger S, Buck A, Mottaghy F, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.PubMedGoogle Scholar
  18. 18.
    Jones MD, Pais MJ, Omiya B. Bony overgrowths and abnormal calcifications about the spine. Radiol Clin North Am. 1988;26:1213–34.PubMedGoogle Scholar
  19. 19.
    Sampath S, Sampath S, Lutz A, Willmann J, Mittra E, Gambhir S, et al. Evaluation of NaF PET/CT, FDG PET/CT, combined NaF/FDG PET/CT and CT alone for detection of bone metastases. J Nucl Med. 2012;53 Suppl 1:586, abstract.Google Scholar
  20. 20.
    Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253–8.PubMedGoogle Scholar
  21. 21.
    Richmond K, McLean N, Rold T, Szczodroski A, Dresser T, Hoffman T. Optimizing a F-18 NaF and FDG cocktail as a preclinical cancer screening tool for molecular imaging. J Nucl Med. 2011;52 Suppl 1:2455. Abstract.Google Scholar
  22. 22.
    Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.PubMedGoogle Scholar
  23. 23.
    Adams M, Turkington T, Wilson J, Wong T. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Delbeke D, Coleman RE, Guiberteau M, Brown M, Royal H, Siegel B, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMedGoogle Scholar
  25. 25.
    Boellaard R, O’Doherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCrossRefGoogle Scholar
  26. 26.
    Niederkohr RD, Greenspan BS, Prior JO, Schöder H, Seltzer MA, Zukotynski KA, et al. Reporting guidance for oncologic 18F-FDG PET/CT imaging. J Nucl Med. 2013;54:756–61. doi: 10.2967/jnumed.112.112177.PubMedCrossRefGoogle Scholar
  27. 27.
    Hillner B, Siegel B, Liu D, Shields A, Gareen I, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Even Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Li Y, Schiepers C, Lake R, Dadparvar S, Berenji G. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50:128–39.PubMedCrossRefGoogle Scholar
  30. 30.
    Kazama T, Swanston N, Podoloff D, Macapinlac H. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Niederkohr R. Technical feasibility vs. clinical utility: a question of “can we?” vs. “should we?”. Eur J Nucl Med Mol Imaging. 2012;39:260–1.PubMedCrossRefGoogle Scholar
  32. 32.
    Cook GJR. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an International Multicenter Trial. J Nucl Med. 2013;54:173–5. doi: 10.2967/jnumed.112.116236.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Andrei Iagaru
    • 1
  • Camila Mosci
    • 2
  • David W. Dick
    • 3
  • Mike Sathekge
    • 4
  • Paula Lapa
    • 5
  • Joao M. de Lima
    • 5
  • Sanjiv Sam Gambhir
    • 2
  1. 1.Division of Nuclear Medicine and Molecular ImagingStanford University Medical CenterStanfordUSA
  2. 2.Department of RadiologyStanford University Medical CenterStanfordUSA
  3. 3.Stanford University Medical CenterStanfordUSA
  4. 4.Pretoria University HospitalPretoriaSouth Africa
  5. 5.Serviço de Medicina NuclearHospitais da Universidade de CoimbraCoimbraPortugal

Personalised recommendations